India’s pharmaceutical manufacturing capabilities are globally recognised, but the distribution layer that connects medicines to pharmacies and patients remains highly fragmented. The challenge, however, is not necessarily that the sector lacks technology. Instead, many of its stakeholders have adopted digital tools in isolation, leaving critical data trapped within disconnected systems.
Sagar Chauhan, Co-Founder and CPTO, DocPharma, believes this “siloed digitisation” is one of the biggest barriers to building a genuinely connected pharmaceutical distribution network.
“Nearly every node runs some software,” says Chauhan. Manufacturers use platforms such as SAP or Oracle, while more than 60,000 stockists and 800,000 retail chemists use desktop billing tools. But many of these systems were originally designed for local accounting, GST and billing rather than functioning as connected nodes within a wider supply network.
As a result, information remains locked in private databases, while distributors have little incentive to expose data relating to margins, informal credit arrangements and customer relationships.
The answer, therefore, is not simply to introduce another software platform. It requires the ecosystem to standardise how medicines are identified, connect legacy systems without disrupting existing workflows and create commercial incentives for stakeholders to share data.
Connecting a fragmented ecosystem
Chauhan identifies three building blocks for this transition.
The first is a unified drug catalogue, with standardised SKU identifiers using frameworks such as GS1/GTIN so that the same formulation is not represented differently across multiple systems.
The second is non-intrusive connectivity. Rather than forcing stockists to replace their existing billing systems, background synchronisation tools can pull inventory and order information without requiring users to change their day-to-day workflows.
The third is commercial incentive. Traditional players need a reason to share live operational data, whether through automated purchase orders, faster invoice clearing or improved returns management for near-expiry stock.
This makes interoperability as much a business problem as a technology problem.
For real-time visibility, Chauhan argues that the industry should avoid trying to force thousands of fragmented legacy players onto a single monolithic platform. Instead, the underlying architecture needs to be modular, event-driven and API-first.
A master data management layer can normalise diverse distributor SKUs against standard salts, brands and pack sizes. An event-driven integration layer can then stream inventory counts, batch allocations and order states rather than relying on delayed batch uploads.
The infrastructure also needs to capture compliance-related information, including batch numbers, FEFO expirations, digital Schedule H/H1 registers and cold-chain temperature logs.
Creating a single source of truth
The interoperability challenge also raises the question of who should take responsibility for connecting the ecosystem.
Chauhan argues that traditional desktop software vendors may have limited incentive to build such connections, while government digital frameworks can establish standards without necessarily providing the operational rails needed to connect every participant.
This creates an opening for specialised pharma-technology infrastructure providers to build bridges between legacy procurement systems and modern digital demand.
DocPharma has approached the problem by controlling more of the fulfilment environment through a dedicated dark-store model. Rather than depending on third-party partner pharmacies for inventory visibility, its model uses dedicated micro-fulfilment hubs.
According to Chauhan, this creates a single source of truth for inventory and reduces issues such as ghost inventory, synchronisation delays and order cancellations.
Within the fulfilment environment, warehouse management system telemetry tracks activities from inward batch scanning and binning through to FEFO-enforced picking and dispatch. Downstream partners such as e-pharmacies, D2C health brands and clinics can then access catalogue and fulfilment information through APIs.
The broader lesson is that real-time visibility becomes difficult when every participant is expected to solve its own interoperability problem. A connected network needs an infrastructure layer that can absorb much of that complexity.
From stock-out response to prediction
Better connectivity could also fundamentally change inventory planning.
Traditional distribution can end up operating in firefighting mode when decisions are based on delayed sales reports. Real-time visibility into orders, inventory and consumption patterns, by contrast, can allow stock placement to become more predictive.
Chauhan points to safety stock as one area where this can have a direct operational impact. Traditional pharma distribution can maintain 30–45 days of safety stock at different nodes to protect against stock-outs. With visibility into consumption velocity and replenishment lead times, he says, dark stores can potentially operate with leaner forward inventory while maintaining fill rates.
Real-time data can also help reduce the bullwhip effect. When a retail outlet begins running low, it may over-order from a distributor, which in turn can over-order from a manufacturer. Better visibility into actual consumption can reduce these distorted demand signals and help stabilise upstream procurement.
The other opportunity is hyper-local demand sensing.
Changes in order behaviour can reveal localised trends, such as sudden increases in demand for anti-allergy or viral medications within specific pin-code clusters, potentially much earlier than traditional sales reports.
The objective is to move from reacting to stock-outs to preventing them.
Automated replenishment can track depletion rates against supplier turnaround times and trigger purchase orders before thresholds are breached. Inventory can also be dynamically balanced between fulfilment hubs. If one location experiences a surge in demand while another holds surplus stock of the same batch, the system can facilitate a transfer before either site faces a stock-out or expiry problem.
FEFO — first expiry, first out — can similarly become more dynamic when the system has live visibility into batches approaching their expiry windows.
Automating coordination, not judgement
For Chauhan, the biggest automation opportunity in pharma distribution is not simply faster warehouse picking. It is eliminating the coordination overhead that currently consumes operational time.
Traditional distribution involves people calling stockists to check availability, matching batches against physical records and manually calculating order quantities. Much of this coordination can be automated.
Inventory replenishment, batch allocation, FEFO picking, regulatory paperwork and cold-chain monitoring are among the processes that can increasingly run through automated systems.
IoT sensors, for instance, can continuously monitor cold-chain conditions and alert teams when temperatures move outside required ranges. Regulatory and dispatch documents such as GST e-invoices, e-way bills and digital Schedule H/H1 registers can also be generated automatically as orders move through the fulfilment process.
But automation has clear boundaries in healthcare.
Prescription and clinical verification still require licensed pharmacist oversight for sensitive medicines. Physical inward checks also require people to inspect packaging, verify manufacturer seals and handle discrepancies. Supplier relationships and unexpected manufacturer-level supply disruptions similarly require human judgement.
The principle is therefore not to remove humans from pharma distribution but to remove unnecessary coordination work so that human expertise remains focused on safety and exceptions.
AI as the intelligence layer
Over the next three to five years, Chauhan expects AI to move beyond descriptive dashboards and become an execution layer for pharma distribution.
AI could predict localised demand by correlating e-prescription trends, seasonal illness patterns and doctor prescribing behaviour. It could balance inventory across regional hubs and dark stores based on demand and expiry velocity. It could also determine the optimal fulfilment node based on inventory availability, transit time, cold-chain requirements and unit economics.
But none of this can happen simply by adding an AI model to existing systems.
“AI is only as good as the operational data underneath it,” Chauhan says.
The industry therefore needs to invest in the foundations first.
That includes strict master-data hygiene, with standardised catalogue mapping and reliable records for batches, inward dates and expiries. It requires real-time telemetry instead of daily reconciliation, capturing information across inwarding, picking velocity, transit times and returns.
It also requires programmable, two-way APIs connecting warehouse management and fleet systems so that AI recommendations can trigger actual purchase orders, pick lists and dispatches rather than simply appearing as suggestions on a dashboard.
Compliance also needs to be embedded into the technology layer, with digital registers and continuous cold-chain logs forming part of the transactional infrastructure.
Building the foundations before autonomy
This is ultimately what will determine whether AI in pharma distribution becomes a collection of isolated pilots or a genuine infrastructure layer.
A predictive system cannot reliably forecast demand if the underlying catalogue is inconsistent. It cannot dynamically route inventory without accurate, real-time information about stock, location, transit and expiry. And it cannot autonomously execute recommendations unless the systems managing procurement, warehouses and fulfilment are connected through programmable interfaces.
The technology roadmap therefore starts with less glamorous but more fundamental work: standardising data, connecting legacy systems, improving telemetry and embedding compliance into transactions.
Once those foundations are in place, AI can begin to operate at a different level — not merely telling supply-chain teams what happened, but helping determine where stock should be placed, when it should be replenished and how it should move through the network.
For India’s pharma distribution ecosystem, that could mark a significant shift. Instead of maintaining large buffers because participants cannot see what is happening elsewhere in the network, real-time intelligence could allow inventory to move closer to actual demand.
And instead of treating medicine availability as a logistics problem that is solved after a stock-out occurs, the industry could increasingly treat it as a data and prediction problem — one where better-connected systems anticipate demand, optimise inventory and reduce the likelihood of shortages before they occur.